Form 4 Filing for MAETZOLD DEREK J

Derek J. Maetzold, President & CEO of CASTLE BIOSCIENCES INC (CSTL), reported a series of transactions on April 6, 2026. These transactions, conducted under a Rule 10b5-1 plan, involved the acquisition of 6,214 shares of Common Stock at $2.39 per share and the disposition of 6,214 shares at a weighted-average price of $25.03. Additionally, several dispositions of Common Stock were made from various trusts, including The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, and several Maetzold 2018 Remainder Trusts. Maetzold also exercised a stock option, acquiring 6,214 shares of Common Stock. Following these transactions, his direct holdings include 27,693 shares, and indirect holdings are substantial, including significant shares in DJM Grantor Retained Annuity Trusts.